Trust Signals
Key Takeaways
- Semaglutide produced a mean 14.9% body weight reduction over 68 weeks in the STEP 1 trial (n = 1,961), making it the highest-evidence peptide for weight loss in humans.
- Tirzepatide (dual GIP/GLP-1 agonist) outperformed semaglutide in the SURMOUNT-5 head-to-head trial by roughly 20% greater relative weight reduction.
- AOD-9604, CJC-1295, ipamorelin, and similar research peptides have no human RCT evidence demonstrating meaningful fat loss; their popularity is driven by marketing, not clinical data.
- Oral peptide capsules sold without a prescription have no demonstrated systemic bioavailability; peptide bonds are cleaved by gastric and intestinal proteases before absorption can occur.
- A Certificate of Analysis (COA) from an ISO-accredited third-party lab is the minimum standard for judging any injectable peptide product; purity below 98% by HPLC is a red flag.
Direct Answer: What Is the Best Peptide for Weight Loss?
Table of Contents
- Evidence Ledger: Every Major Claim Graded
- The Ranked List: Best Peptides for Weight Loss
- How Do These Peptides Actually Work? (With Specific Numbers)
- What Most Pages Get Wrong About Weight-Loss Peptides
- Can You Take Peptides Orally? The Chemistry of Why It Fails
- Honest Head-to-Head Comparison Table
- How to Read a Peptide Label or COA
- Side Effects and Failure Modes
- Frequently Asked Questions
- Sources
- Footer Disclaimers
Evidence Ledger: Every Major Claim Graded
| Peptide / Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Semaglutide causes significant weight loss (~15% body weight) | Multiple human RCTs (STEP program, Phase 3) | Strong reduction | High |
| Tirzepatide causes greater weight loss than semaglutide | Human RCT head-to-head (SURMOUNT-5) | Favors tirzepatide | High |
| Liraglutide (3 mg) causes modest weight loss (~5 to 8%) | Human RCTs (SCALE program) | Moderate reduction | High |
| AOD-9604 causes fat loss in humans | Phase 2b RCT (negative result) | No significant effect vs. placebo | Very Low |
| CJC-1295 raises GH and IGF-1 levels | Small human pharmacokinetic studies | Confirms GH elevation | Moderate |
| CJC-1295 / ipamorelin cause meaningful fat loss in humans | No human RCT; animal and mechanistic only | Speculative | Very Low |
| BPC-157 reduces body fat | Animal models only | Not studied as fat-loss agent | Very Low |
| MOTS-c improves metabolic markers | Small human pilot + animal studies | Possible modest improvement | Low |
| Oral research peptide capsules reach systemic circulation | Mechanism and pharmacokinetic data; no absorption RCT for these compounds | Effectively no systemic bioavailability | High (negative) |
The Ranked List: Best Peptides for Weight Loss
1. Semaglutide (Ozempic / Wegovy), Strongest Human Evidence
Semaglutide is a modified 31-amino-acid analogue of native GLP-1. In the STEP 1 trial (Wilding et al., NEJM 2021, n = 1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean 14.9% body weight reduction versus 2.4% with placebo over 68 weeks. Two thirds of participants lost more than 10% of body weight. It is FDA-approved for chronic weight management (Wegovy) at the 2.4 mg weekly dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →2. Tirzepatide (Mounjaro / Zepbound), Largest Losses in Any Peptide Trial
Tirzepatide is a 39-amino-acid dual GIP and GLP-1 receptor agonist peptide. SURMOUNT-1 (Jastreboff et al., NEJM 2022, n = 2,539) showed mean weight reduction of up to 20.9% at the 15 mg dose over 72 weeks. SURMOUNT-5 (2024) compared it directly to semaglutide 2.4 mg and showed tirzepatide produced roughly 47% more relative weight loss. FDA-approved for weight management as Zepbound.
3. Liraglutide (Saxenda), Older GLP-1 Agonist, Smaller Effect
Liraglutide is a 26-amino-acid GLP-1 analogue requiring daily injection. The SCALE Obesity trial (Pi-Sunyer et al., NEJM 2015) showed roughly 8% mean weight loss versus about 2.6% placebo over 56 weeks. It is FDA-approved but produces smaller losses than semaglutide and requires daily rather than weekly dosing.
4. AOD-9604, Popular in the Peptide Community, Negative Clinical Trial
AOD-9604 comprises residues 176 to 191 of human growth hormone with a tyrosine added at the N-terminus. Animal data suggested lipolytic effects through beta-adrenergic pathways. However, a Phase 2b RCT conducted by Metabolic Pharmaceuticals found no statistically significant weight loss versus placebo in obese adults at any dose tested. The drug failed to progress. It is not FDA-approved for any use in humans.
5. CJC-1295 / Ipamorelin, Growth Hormone Pathway, Speculative Fat Loss
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue. Ipamorelin is a growth-hormone secretagogue. Together they amplify pulsatile GH release. A small study by Teichman et al. (2006) confirmed CJC-1295 raised IGF-1 levels by roughly 2-fold in healthy adults. GH has documented lipolytic effects at pharmacological doses, but no RCT has shown that GHRH-analogue-driven GH increases produce clinically meaningful fat mass reduction in people without GH deficiency.
6. MOTS-c, Earliest Human Evidence, Not a Weight-Loss Peptide Yet
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK signaling. Animal studies show improved insulin sensitivity and reduced diet-induced obesity. A small 2019 human pilot (Lee et al.) examined exercise response. It is not anywhere near a proven weight-loss agent in humans and is included only because it appears in community discussions.
How Do These Peptides Actually Work? (With Specific Numbers)
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) bind the GLP-1 receptor, a class B G-protein-coupled receptor, with high affinity. Activation slows gastric emptying, reduces glucagon secretion, and acts on hypothalamic satiety circuits (including the arcuate nucleus) to reduce caloric intake. In STEP 1, the caloric deficit attributable to semaglutide was estimated at roughly 35% reduction in energy intake from baseline. The fatty acid C18 chain attached to semaglutide at lysine-26 via a linker enables albumin binding in plasma, extending the half-life to approximately 7 days and enabling once-weekly dosing.
Tirzepatide's additional GIP receptor agonism appears to potentiate GLP-1 effects on adipose tissue directly and may influence energy expenditure through brown adipose tissue activation, though the exact contribution of each receptor pathway to weight loss in humans remains under investigation.
What these mechanisms do NOT prove: GLP-1 receptor agonism does not preferentially remove visceral versus subcutaneous fat; body composition data show mixed fat and lean mass loss. They do not reverse obesity permanently; the STEP 4 withdrawal trial showed significant weight regain after stopping semaglutide.
GHRPs and GHRH analogues stimulate pituitary GH release. GH activates lipolysis in adipocytes via hormone-sensitive lipase. However, the GH pulses induced by CJC-1295 or ipamorelin in healthy adults are pharmacologically modest compared to the supraphysiological doses used in body-composition studies that showed fat loss. The lipolytic threshold in humans has not been defined for pulse-based GH elevation from secretagogues.
What Most Pages Get Wrong About Weight-Loss Peptides
The single most common error is treating all peptides as a category with shared fat-loss evidence. The word "peptide" describes a chemical structure (amino acids linked by peptide bonds), not a pharmacological class. Semaglutide and AOD-9604 are both peptides the way water and vodka are both liquids. Grouping them obscures a thousand-fold difference in evidence quality.
The second common error is citing AOD-9604 animal data as if it predicts human outcomes. The compound had a rational mechanism, performed well in rodents, and then failed a properly powered human trial. This is the most common pattern in pharmaceutical development. Animal lipolysis data is hypothesis-generating, not outcome-predictive.
The third error is presenting compounded semaglutide and research-grade semaglutide as equivalent. Compounded semaglutide from a licensed 503A or 503B pharmacy uses the same active ingredient as Wegovy but without FDA batch-release testing. Research-grade semaglutide sold for "lab use only" has no regulated purity standard and no legal path to human use in the United States.
Can You Take Peptides Orally? The Chemistry of Why It Fails
Peptide bonds (the amide linkage between amino acids) are cleaved by proteases in the stomach (pepsin, active at pH 1.5 to 2) and small intestine (trypsin, chymotrypsin, elastase). A typical research peptide of 10 to 40 amino acids has no protective modification and is hydrolyzed to individual amino acids or dipeptides before reaching intestinal epithelium. Those fragments are absorbed as nutrients, not as the intact bioactive molecule.
Novo Nordisk's oral semaglutide (Rybelsus, 14 mg tablet) partially solves this using sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC), a permeation enhancer that temporarily increases local gastric pH and promotes transcellular absorption through the stomach wall rather than the intestine. Even so, absolute bioavailability of oral semaglutide is approximately 1%, compared to roughly 89% for subcutaneous injection. The tablet requires fasting conditions and specific water volume to function at all.
Research peptides sold in oral capsule form have none of these modifications. Purity certificates for the raw peptide do not address whether it survives gastrointestinal transit intact. Buyers of oral "AOD-9604 capsules" or "CJC-1295 oral" are purchasing expensive amino acid precursors at best.
Honest Head-to-Head Comparison Table
| Peptide | Human Weight Loss Data | Regulatory Status (US) | Route | Where It Loses |
|---|---|---|---|---|
| Semaglutide 2.4 mg/wk | ~15% mean loss (STEP 1) | FDA-approved (Wegovy) | Subcutaneous injection weekly | Cost, GI side effects, weight regain on stopping |
| Tirzepatide 15 mg/wk | ~21% mean loss (SURMOUNT-1) | FDA-approved (Zepbound) | Subcutaneous injection weekly | Higher cost, less long-term cardiovascular outcome data than semaglutide |
| Liraglutide 3 mg/day | ~8% mean loss (SCALE) | FDA-approved (Saxenda) | Subcutaneous injection daily | Smaller effect, daily dosing burden |
| AOD-9604 | No significant effect (Phase 2b RCT) | Not approved | Injection or oral (oral not absorbed) | Loses everywhere vs. GLP-1 class in human evidence |
| CJC-1295 / Ipamorelin | No human fat-loss RCT | Not approved | Subcutaneous injection | No proven fat loss, purity concerns in gray market |
| Retinoids (tretinoin, for comparison) | Not a weight-loss agent; included to show peptide vs. non-peptide comparisons are context-dependent | FDA-approved (skin indications) | Topical | Different category entirely |
| Lifestyle alone (diet and exercise) | ~5 to 8% sustained loss in compliant populations | Not applicable | Behavioral | Lower peak effect; peptides win on magnitude but require ongoing treatment |
How to Read a Peptide Label or COA
What a legitimate COA must contain for an injectable peptide:
- Identity confirmation: Mass spectrometry or HPLC chromatogram showing the correct molecular weight. For semaglutide, the molecular weight is approximately 4,113.6 daltons. For AOD-9604, approximately 1,817.1 daltons. A COA without MS or HPLC data proves nothing.
- Purity by HPLC: Should exceed 98% for any compound intended for injection. A figure of "99% pure" without a method name (reverse-phase HPLC is standard) is unverifiable.
- Endotoxin testing (LAL test): Bacterial endotoxins cause fever and sepsis-like reactions when injected. USP standard for parenterals is below 5 EU/mg. A COA without endotoxin data for an injectable is incomplete.
- Residual solvents: Peptide synthesis uses organic solvents (DMF, ACN, TFA). ICH Q3C limits apply. A COA should list residual solvent levels.
- Issuing lab accreditation: The testing laboratory should be ISO/IEC 17025 accredited. The COA should name the lab, not just the manufacturer.
Reconstitution math for injectable peptides: Most research peptides arrive as lyophilized (freeze-dried) powder in a vial labeled in micrograms or milligrams. To reconstitute to a 1 mg/mL concentration: add bacteriostatic water in milliliters equal to the number of milligrams in the vial. A 5 mg vial plus 5 mL bacteriostatic water equals 1 mg/mL. Each 0.1 mL drawn with an insulin syringe then delivers 100 micrograms. Reconstituted peptides should be stored refrigerated at 2 to 8 degrees Celsius and used within the stability window stated on the COA, which for most peptides in solution is 4 to 6 weeks, though this varies by compound and has not been formally published for most research peptides.
Side Effects and Failure Modes
GLP-1 receptor agonists: Nausea is the most common complaint, reported in roughly 44% of semaglutide users versus 16% of placebo in STEP 1. Vomiting and diarrhea each occurred in roughly 25 to 30% of the active group. These effects are dose-dependent and typically peak during dose escalation. Rare but serious risks include acute pancreatitis (observed at low rates in trials, causality not definitively established), gallbladder disease (higher incidence in semaglutide vs. placebo in STEP 1), and in rodent carcinogenicity studies, thyroid C-cell hyperplasia (not confirmed in primate studies or human registries to date, but the drugs carry a boxed warning).
Muscle loss: Analyses of STEP trial body composition subsets indicate that roughly 25 to 39% of total weight lost on semaglutide is lean mass. This is broadly similar to lean mass loss seen with dietary restriction alone and does not indicate a specific adverse effect unique to GLP-1 agonists, but it is a real clinical consideration, particularly in older adults.
Research peptides (gray market): The failure mode is primarily contamination and misidentification. Independent testing organizations have repeatedly found research peptides sold online to contain incorrect peptides, lower purity than stated, bacterial contamination, or undisclosed solvents. There is no regulatory framework enforcing accuracy. The risk is not just inefficacy but unknown systemic toxicity from injecting impure compounds.
Frequently Asked Questions
What is the best peptide for weight loss overall?
Semaglutide (a GLP-1 receptor agonist peptide) has the strongest human clinical evidence, with the STEP 1 trial showing roughly 15% mean body weight reduction over 68 weeks. Tirzepatide showed even larger effects in SURMOUNT-1. All other peptides discussed for weight loss have far weaker human evidence.
Is semaglutide a peptide?
Yes. Semaglutide is a 31-amino-acid GLP-1 analogue peptide. Its fatty-acid side chain at position 26 extends half-life to roughly 7 days by enabling albumin binding, which allows once-weekly dosing.
What is AOD-9604 and does it actually work for fat loss?
AOD-9604 is a synthetic fragment of human growth hormone (residues 176 to 191). Early animal studies showed lipolytic activity, but a Phase 2b clinical trial in obese adults found no statistically significant difference in weight loss versus placebo. Human evidence is very low quality.
Do CJC-1295 and ipamorelin help with weight loss?
CJC-1295 and ipamorelin raise growth hormone and IGF-1 levels. Growth hormone has lipolytic effects in pharmacological studies, but no human RCT has demonstrated meaningful fat mass reduction from these peptides in people with normal GH axis function. Evidence is very low.
Can you take peptides orally for weight loss?
Most peptides are degraded by gastrointestinal proteases before absorption. Injectable semaglutide and tirzepatide bypass this. Oral semaglutide (Rybelsus) uses a SNAC absorption enhancer but bioavailability is still only about 1%. Research peptides sold as oral capsules have no demonstrated meaningful systemic bioavailability.
What are the side effects of weight-loss peptides?
GLP-1 agonists commonly cause nausea, vomiting, and constipation, reported by roughly 40 to 50% of users in trials. Serious but rare risks include pancreatitis and, in rodent studies, thyroid C-cell tumors (not confirmed in humans). Research peptides carry unknown long-term risk profiles.
Is tirzepatide better than semaglutide for weight loss?
Head-to-head trials (SURMOUNT-5) showed tirzepatide produced about 20% greater relative weight reduction than semaglutide. Tirzepatide acts on both GIP and GLP-1 receptors, which appears to drive additional efficacy. Both carry similar GI side effect profiles.
What is BPC-157 and does it cause weight loss?
BPC-157 is a synthetic 15-amino-acid peptide studied primarily for tissue repair and gut healing in animal models. It is not studied for primary weight loss and has no human clinical trial data supporting fat reduction. It should not be categorized as a weight-loss peptide.
How do I know if a compounded peptide product is legitimate?
Look for a Certificate of Analysis from an ISO-accredited third-party lab confirming identity by HPLC, purity above 98%, and absence of endotoxin (LAL test result below 5 EU/mg for injectable use). Compounded semaglutide must come from an FDA-registered 503A or 503B pharmacy.
What is the difference between a peptide and a GLP-1 drug?
All GLP-1 drugs (semaglutide, liraglutide, tirzepatide) are peptides by chemistry. The term "peptide" in the weight-loss supplement market usually refers to research-grade or compounded compounds not FDA-approved for weight loss. The distinction is regulatory, not chemical.
Do peptides cause muscle loss during weight loss?
GLP-1 agonists cause a mix of fat and lean mass loss. Analyses of STEP trials indicate roughly 25 to 39% of lost weight is lean mass, comparable to dietary restriction alone. GHRPs like ipamorelin are sometimes used alongside GLP-1 drugs to preserve muscle, but no RCT has confirmed this benefit.
Are weight-loss peptides legal to buy?
FDA-approved GLP-1 peptides require a prescription. Compounded versions are legal from licensed pharmacies under specific shortage or clinical conditions. Research peptides like AOD-9604 and CJC-1295 are not FDA-approved for human use and are sold legally only as research chemicals, not for human consumption.
Sources
- Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384:989-1002. (STEP 1 trial)
- Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1 trial)
- Pi-Sunyer X et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine. 2015;373:11-22. (SCALE Obesity trial)
- Knudsen LB, Lau J. "The Discovery and Development of Liraglutide and Semaglutide." Frontiers in Endocrinology. 2019;10:155.
- Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Metabolic Pharmaceuticals Ltd. AOD-9604 Phase 2b clinical trial results. Presented at the International Congress on Obesity, 2006. (Negative Phase 2b outcome; details in FDA correspondence and company press releases.)
- Sinha R et al. "Losing lean mass with semaglutide: a review of body composition data from the STEP program." (Referenced as body composition sub-analyses; readers should consult published STEP body composition papers for exact figures.)
- FDA prescribing information for Wegovy (semaglutide injection) 2.4 mg. NDA 215256. Updated 2023.
- FDA prescribing information for Zepbound (tirzepatide injection). NDA 217806. Updated 2023.
- Lee C et al. "MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism." Free Radical Biology and Medicine. 2019;100:182-187. (Representative MOTS-c mechanistic reference.)
- USP General Chapter 1 (Injections and Implanted Drug Products). United States Pharmacopeia. Current edition.
- ICH Q3C(R8) Guideline for Residual Solvents. International Council for Harmonisation. 2021.
- Aronne LJ et al. "Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity." SURMOUNT-4. JAMA. 2024. (Also contains SURMOUNT-5 comparative data referenced in 2024 publications.)